The toll-like receptor 1 variant S248N influences placental malaria

Lutz Hamann1, George Bedu-Addo, Teunis A Eggelte

  • 1Institute for Microbiology and Hygiene, Charité - University Medical Center, Dorotheenstrasse 96, 10117 Berlin, Germany. lutz.hamann@charite.de

In malaria-endemic regions, Plasmodium falciparum infection in pregnancy is a predominant cause of maternal and infant morbidity and mortality. Primiparae are relatively immune-naïve and particularly prone. Innate immune recognition of P. falciparum is partly mediated by Toll-like receptors (TLRs), and single nucleotide polymorphisms (SNPs) of TLR-4 and -9 influence manifestation. Recognition via TLR-2, which functions as heterodimer with TLR-1 or TLR-6, appears to be essential but in previous studies from Ghana, functional TLR-2 SNPs were virtually absent. In the present study, we assessed two well characterized TLR-1 polymorphisms, rs4833095 (S248N) and rs5743618 (I602S), among 302 primiparous Ghanaian women, and analysed associations with P. falciparum infection and manifestation. The prevalence of the TLR-1 S248N variant was 20.5%, whereas the TLR-1 I602S variant was rare at 2%. Placental P. falciparum infection was observed in 78% of women heterozygous for the TLR-1 S248N SNP but in 63% of women with the respective wildtype (P=0.03). Furthermore, the odds of malaria-associated anaemia were more than doubled in TLR-1 S248N heterozygous women (P=0.03) although parasite densities did not differ. No differences in the rates of low birth weight and preterm delivery were observed. These data support that TLR-1 is involved in the recognition of P. falciparum and indicate its role in susceptibility to and manifestation of malaria in pregnancy.

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...